Eledon Pharmaceuticals, Inc. (ELDN) Investment Analysis
1. Executive Summary
Eledon Pharmaceuticals, Inc. (ELDN) represents a high-conviction narrative in the clinical-stage biotechnology sector, specifically positioned within the multi-billion-dollar immunology and organ transplantation markets.[1, 2, 3] The company's strategic mission is predicated on the development of tegoprubart (formerly AT-1501), a humanized monoclonal antibody designed to target the CD40 Ligand (CD40L, also known as CD154).[4, 5, 6] The foundational thesis for Eledon is the replacement of the current standard of care in transplantation—calcineurin inhibitors (CNIs), primarily tacrolimus—which, despite being effective at preventing acute rejection, is characterized by significant long-term toxicities including nephrotoxicity, neurotoxicity, and metabolic dysfunction.[7, 8, 9]
The economic engine of Eledon is currently pre-revenue, with its value derived from the progression of its lead candidate through registrational clinical trials.[9, 10] The company primarily targets the de novo kidney transplant market, which is the most common organ transplant procedure globally, while simultaneously expanding into high-unmet-need niches such as pancreatic islet cell transplantation for Type 1 Diabetes (T1D), liver transplantation, and the nascent field of xenotransplantation.[3, 11] Geographically, the company operates out of Irvine, California, and Cambridge, Massachusetts, but its target markets are global, focusing on the Seven Major Markets (7MM) where advanced transplantation infrastructure exists.[11, 12, 13, 14]
Eledon’s primary customers will eventually be transplant surgeons and specialized medical centers that perform approximately 172,409 organ transplants annually worldwide.[2] These professionals choose therapies based on a balance of efficacy (organ survival) and safety (patient quality of life).[8] Current alternatives like tacrolimus are available as inexpensive generics but carry a heavy burden of side effects; for instance, tacrolimus users exhibit significantly higher rates of tremors and new-onset diabetes compared to patients in Eledon's clinical trials.[8, 15, 16] Tegoprubart offers a non-toxic alternative that aims to preserve renal function—measured by the estimated glomerular filtration rate (eGFR)—more effectively than the current standard.[3, 13]
| Feature |
Tegoprubart Profile |
Standard of Care (Tacrolimus) |
| Primary Target |
CD40L (Costimulation Blockade) |
Calcineurin (Intracellular Signaling) |
| Organ Preservation |
High (eGFR improvement observed) |
Low (Chronic nephrotoxicity) |
| Safety Concerns |
Minimal (Well-tolerated in >100 humans) |
Tremors, Diabetes, Hypertension |
| Regulatory Status |
Phase 2 Complete / Phase 3 Ready |
FDA Approved (Generic) |
| Market Potential |
First-in-class potential for CD40L |
Commodity/Generic Market |
[1, 3, 7, 8, 9]
Strategically, Eledon is positioned to capitalize on the increasing donor pool enabled by machine perfusion and xenotransplantation, acting as the "cornerstone" immunosuppressive regimen for these next-generation technologies.[3, 17] The company’s financial health is bolstered by a cash position of $133.3 million as of year-end 2025, providing a runway into 2027 to achieve critical regulatory and clinical milestones.[1, 10, 18] In summary, Eledon offers exposure to a potential paradigm shift in a market that has seen little mechanistic innovation in over three decades.
2. Business Drivers & Strategic Overview
The valuation of Eledon Pharmaceuticals is almost entirely driven by the clinical success and commercial potential of tegoprubart.[9] To understand what is actually being sold, an investor must look at the biochemistry of the CD40L pathway. Tegoprubart is a humanized IgG1 monoclonal antibody with high affinity for the CD40 Ligand.[6] The CD40L/CD40 interaction is the critical "Signal 2" in the T-cell activation process.[19] In a transplant setting, Signal 1 occurs when the patient's T-cells recognize the donor organ as foreign.[7] However, for those T-cells to fully activate and begin an inflammatory attack (rejection), they require a second costimulatory signal.[19] By blocking CD40L, tegoprubart effectively "blinds" the immune system to the presence of the foreign organ without broadly suppressing the entire immune system in a toxic manner.[6, 8]
The Competitive Moat: Intellectual Property and Mechanism
Eledon’s moat is constructed from a multi-layered intellectual property strategy and the inherent technical challenges of targeting the CD40L pathway.
- Patent Protection: The company’s IP portfolio is extensive. Method of manufacture patents for tegoprubart are expected to last until February 2036.[10] Core therapeutic antibody patents extend through May 2038.[10] Most importantly, pending applications for specific indications like kidney and neurodegenerative disorders could push exclusivity as far as November 2046.[10] This provides a durable runway for pricing power.
- Engineering Advantage: Historical attempts to target CD40L failed in the early 2000s because early antibodies caused blood clots (thromboembolism) due to their interaction with platelets.[19] Tegoprubart was specifically engineered with a modified "silenced" Fc region that does not bind to the receptors on platelets, thereby eliminating the clotting risk.[7, 19] This engineering represents a significant barrier to entry for biosimilars or "fast followers."
- Regulatory Exclusivity: Tegoprubart has received Orphan Drug designation from the FDA for the prevention of allograft rejection in liver transplantation, islet cell transplantation, and for the treatment of ALS.[5, 20] These designations provide seven years of market exclusivity upon approval and tax credits for clinical trials.[18]
- Switching Costs: In the transplant world, switching costs are essentially infinite once a patient is stable on a regimen. Surgeons are extremely hesitant to change the immunosuppressive drugs of a patient with a functioning organ, creating a "locked-in" lifetime revenue stream once a drug is initiated at the time of transplant.[2, 21]
Market Opportunity and TAM Analysis
The Total Addressable Market (TAM) for tegoprubart is segmented across its various indications, with de novo kidney transplant representing the largest opportunity.
| Market Segment |
2024 Size |
2034 Projection |
CAGR |
| Global Immunosuppressants |
\$5.55 Billion |
\$8.82 Billion |
4.74% |
| Kidney Transplant (7MM) |
\$4.26 Billion |
\$6.65 Billion |
5.07% |
| Total Kidney Market (Projected) |
\$9.24 Billion (2024) |
\$13.79 Billion (2030) |
6.98% |
[2, 11, 17]
The increase in the number of transplants is driven by rising rates of end-stage renal disease (ESRD) and advancements in organ preservation, such as normothermic machine perfusion, which expands the pool of usable organs.[2, 17] Furthermore, the "functional cure" market for T1D via islet cell transplantation represents a blue-ocean opportunity. If tegoprubart enables islet cells to survive without CNI toxicity, it could unlock a market of millions of insulin-dependent diabetics who currently do not qualify for transplants due to the risks of older drugs.[4]
Competitive Landscape: Positioning and Momentum
Eledon is currently the leader in the clinical development of anti-CD40L therapies for transplantation.[3, 22] However, it faces competition from several large-cap and mid-cap entities.
- Sanofi (Frexalimab): The most direct competitor, frexalimab is an anti-CD40L antibody in Phase 3 for multiple sclerosis and Phase 2 for kidney transplantation.[22, 23, 24] Sanofi’s entry into the space validates the target but poses a significant threat given its massive commercial infrastructure.[22]
- Biogen / UCB (Dapirolizumab pegol): This Fc-free anti-CD40L candidate is in Phase 3 for Systemic Lupus Erythematosus (SLE).[22, 25] While not currently focused on transplantation, it remains a mechanistically relevant competitor.
- Bristol-Myers Squibb (Belatacept/Nulojix): The first-generation costimulation blocker (anti-CD28).[19] While superior to CNIs in preserving kidney function, it has a high rate of acute rejection, which tegoprubart aims to avoid by targeting a different part of the immune synapse.[19, 26, 27]
- Xenotransplantation Specialists (eGenesis): Rather than a competitor, companies like eGenesis are strategic partners. Tegoprubart has been used in human pig-kidney transplants at MGH, positioning Eledon as the "operating system" for the future of cross-species organ supply.[3, 28]
Eledon appears to be gaining ground relative to standard therapies, as evidenced by the BESTOW Phase 2 results which met non-inferiority endpoints while showing clear safety advantages.[3, 8] The company is transitioning from a data-generation phase to a registrational-enabling phase, which is a critical pivot for investors.[9]
3. Financial Performance & Valuation
Eledon Pharmaceuticals reported its most recent financial and operating results for the fourth quarter and full year ended December 31, 2025, on March 19, 2026.[1, 29] As a development-stage entity, the company remains pre-revenue, but its financial performance on the bottom line exceeded market expectations during the reporting period.[29, 30]
Latest Earnings and Financial Health
For the fourth quarter of 2025, Eledon reported an Earnings Per Share (EPS) of -\$0.10, which beat the analyst consensus estimate of -\$0.20 by \$0.10 (a 50% surprise).[29] For comparison, the EPS in the prior year's fourth quarter was -\$0.64.[29] The company reported \$0 in revenue, which was in line with expectations, as no commercial products have yet been launched.[30]
| Financial Metric (FY 2025) |
Amount (USD) |
Change vs. 2024 |
| Total Cash & Short-Term Investments |
\$133.3 Million |
-\$6.9 Million |
| Working Capital |
\$117.3 Million |
Strong Liquidity |
| R&D Expenses |
\$66.3 Million |
+27.5% YoY |
| G&A Expenses |
\$17.0 Million |
-8.6% YoY |
| GAAP Net Loss |
\$45.6 Million |
+\$9.4M (Wider Loss) |
| Adjusted Net Loss (Non-GAAP) |
\$79.1 Million |
+\$12.0M (Wider Loss) |
[1, 10, 20]
The increase in R&D spending to \$66.3 million was primarily driven by the clinical activity surrounding the BESTOW trial and the necessary manufacturing scale-up for Phase 3.[1, 20] Conversely, G&A expenses decreased slightly to \$17.0 million, reflecting operational discipline and lower stock-based compensation costs.[1, 20] A significant factor in the GAAP net loss is the non-cash gain or loss from the change in fair value of warrant liabilities. In 2025, this resulted in a non-cash gain of \$33.4 million, which partially offset the operating loss.[1, 20]
Management Commentary and Analyst Response
During the March 2026 earnings materials and subsequent conference participation at Leerink Partners, CEO David-Alexandre Gros emphasized that the company had achieved non-inferiority in the BESTOW trial.[8] He noted that while statistical superiority in eGFR was not achieved, this was likely due to the "distribution of highest quality deceased donor organs" being imbalanced toward the control arm.[8] The management's focus remains on finalized Phase 3 trial designs with the FDA by the end of 2026.[8]
The market response to the latest results and the March clinical updates was generally positive. Following the March 19th report, the stock saw increased volume and maintained its upward trend.[30] Analyst price targets have remained buoyant, with an average target of \$8.16, representing a potential upside of approximately 144% from current trading levels.[31, 32, 33]
Valuation Drivers and 5-Year Assumptions
Valuing Eledon requires a forward-looking assessment of tegoprubart's peak sales potential. Most valuation models assume a 2028 or 2029 commercial launch.
- 5-Year Sales Growth: Analysts project annual revenue to scale from \$0 in 2027 to \$111 million by 2029 and potentially \$205 million by 2032.[32]
- Operating Drivers: The primary valuation driver is the "eGFR Advantage." If tegoprubart can consistently show an eGFR improvement (as seen in the Phase 1b extension where mean eGFR rose from 67 to 74.2 over 24 months), it could command premium pricing compared to generic tacrolimus.[13]
- Share Count and Funding: The company’s proposal to increase authorized shares to 450 million suggests future dilution is incoming.[34] A realistic 5-year model must account for the share count growing from the current ~77 million to potentially 130-150 million to fund registrational trials.[34]
| Year |
Revenue Est (M) |
EPS Est |
Driver |
| 2026E |
\$0 |
-\$0.87 |
Phase 3 Initiation |
| 2027E |
\$0 |
-\$0.85 |
Phase 3 Progress |
| 2028E |
\$22 |
-\$0.90 |
Early Milestones |
| 2029E |
\$111 |
-\$0.75 |
Commercial Launch |
| 2030E |
\$119 |
+\$0.30 |
Profitability Inflection |
[32, 35, 36]
The valuation is inextricably tied to the "Probability of Technical and Regulatory Success" (PTRS). For a Phase 3-ready asset in a well-validated pathway (CD40L), PTRS typically ranges from 50% to 70%.
4. Risk Assessment & Macroeconomic Considerations
Investing in Eledon Pharmaceuticals involves a complex matrix of risks that could deviate the company from its projected path. These risks range from binary clinical outcomes to structural challenges in the healthcare market.
Company-Specific and Clinical Risks
- Phase 3 Endpoint Failure: The most acute risk is the failure to replicate Phase 2 non-inferiority results in a larger, multicenter Phase 3 trial. While Phase 2 showed a 22.2% rejection rate for tegoprubart vs. 17.2% for tacrolimus (within the non-inferiority margin), a slight deviation in Phase 3 could lead to a trial failure.[3]
- Class-Wide Safety Signals: Any emergence of thromboembolic events—even if not seen in Phase 1 or 2—would be catastrophic for the valuation given the history of the CD40L class.[7, 19]
- The eGFR "Icing" Risk: Management has called superior eGFR "icing on the cake".[8] However, if the drug is approved but fails to show meaningful eGFR superiority, its commercial adoption could be limited to patients who simply cannot tolerate tacrolimus, rather than becoming the new standard for everyone.[8, 9]
Competitive and Regulatory Risks
- Fast-Follower Competition: Sanofi is a formidable competitor. If Sanofi’s frexalimab reaches the market first or shows superior data in kidney transplant, Eledon’s first-mover advantage would be eroded.[14, 22]
- Regulatory Design: The FDA's feedback on Phase 3 trial size and duration is a major risk. If the agency requires a 2-year endpoint for kidney function instead of a 1-year endpoint, the time to market would be pushed back, increasing the need for additional financing.[8, 9]
Balance Sheet and Capital Risks
- Dilution: With a cash burn rate exceeding \$60-80 million annually (adjusted), Eledon is guaranteed to need more capital before 2028.[1, 20] The current proposal to increase authorized common shares from 300 million to 450 million is a clear signal that existing shareholders will be diluted.[34]
- Capital Allocation: The company is pursuing multiple indications (Kidney, Islet, Liver, ALS). Spreading resources too thin could delay the primary kidney program.[5, 10]
Macroeconomic and Industry Structure Risks
- Pricing and Reimbursement: The US market is increasingly sensitive to drug pricing. Generic tacrolimus is highly cost-effective.[15, 21] Tegoprubart, as a biologic, will likely be priced at a significant premium. If payers do not see a clear "value-based" reason (e.g., fewer readmissions, longer organ life), they may impose strict step-therapy requirements.[16, 26]
- Interest Rate Sensitivity: As a pre-profitability biotech, Eledon is a "long-duration" asset. Higher-for-longer interest rates increase the discount rate applied to future cash flows, negatively impacting the current stock price.[30]
| Risk Type |
Early Warning Sign |
Thesis-Ending Event |
| Clinical |
Patient tremors in Phase 3 > 5% |
Failure to show safety advantage over Tacrolimus |
| Regulatory |
FDA demands 3-year safety follow-up |
Massive delay/unaffordable trial cost |
| Financial |
Debt issuance at > 12% interest |
Inability to access equity markets |
| Competitive |
Sanofi reports Phase 2 eGFR > 80 |
Loss of competitive edge to Big Pharma |
[8, 9, 20]
SIGNIFICANT REGULATORY DEPENDENCY.
5. 5-Year Scenario Analysis
The following scenarios analyze Eledon’s potential total return over the next five years (through 2031). These estimates are based on the successful (or unsuccessful) commercialization of tegoprubart.
Base Case (Probability: 50%)
In the base case, Eledon receives FDA approval for tegoprubart in de novo kidney transplant in late 2028. The company successfully transitions to a commercial entity, focusing on top-tier US transplant centers. It secures a partnership for the EU market, providing non-dilutive capital.
- Key Fundamentals: 2031 revenue of \$150 million (representing ~5% market penetration in the 7MM).[32] The company reaches operating break-even in late 2030.
- Valuation Assumptions: A terminal Price/Sales multiple of 5.0x is applied to 2031 revenue, which is conservative for a high-margin biologic with long patent runway.
- Share Count: Estimated at 135 million after two additional equity raises.
- Target Price: \$5.55 per share.
High Case (Probability: 25%)
The high case assumes tegoprubart becomes the primary immunosuppressant for xenotransplantation and receives accelerated approval for T1D islet cell transplantation. Eledon is acquired by a large pharmaceutical company in 2029 for a significant premium.
- Key Fundamentals: 2031 revenue of \$400 million due to multiple indication launches and rapid adoption in the xenotransplant sector.[3, 17]
- Valuation Assumptions: An acquisition multiple or a P/S multiple of 8.0x reflecting the strategic value of the CD40L platform.
- Share Count: 110 million (less dilution due to early partnership).
- Target Price: \$29.09 per share.
Low Case (Probability: 25%)
The low case assumes Phase 3 trials demonstrate non-inferiority but fail to show superior safety or kidney function. The FDA grants approval with a restrictive label. Commercial adoption is slow, and the company is forced to raise capital at distressed valuations.
- Key Fundamentals: 2031 revenue of \$30 million. Chronic operating losses continue.
- Valuation Assumptions: A distressed asset multiple of 1.0x P/S.
- Share Count: 200 million due to excessive equity financing.
- Target Price: \$0.15 per share.
Scenario Comparison Table
| Scenario |
2031 Revenue |
Operating Margin |
P/S Multiple |
Current Price |
Implied Price |
5-Yr Return |
Annualized |
Prob % |
| High |
\$400M |
35% |
8.0x |
\$3.34 |
\$29.09 |
+771% |
54.1% |
25% |
| Base |
\$150M |
15% |
5.0x |
\$3.34 |
\$5.55 |
+66% |
10.7% |
50% |
| Low |
\$30M |
-25% |
1.0x |
\$3.34 |
\$0.15 |
-95% |
-45.1% |
25% |
| Weighted |
\$182M |
17.5% |
5.75x |
\$3.34 |
\$10.08 |
+201% |
24.7% |
100% |
Note: Expected outcome uses probability-weighted target of ~$10.08.
ASYMMETRIC GROWTH PROFILE.
6. Qualitative Scorecard
| Metric |
Score (1-10) |
Narrative |
| Management Alignment |
7 |
CEO David-Alexandre Gros and executive officers have competitive total compensation packages with a heavy emphasis on stock-based incentives (>$3M for CEO in 2025).[34] However, direct insider ownership as a percentage of total shares remains low (~0.06%).[37] |
| Revenue Quality |
1 |
Currently pre-revenue. All future revenue is contingent on binary clinical outcomes.[9, 10] |
| Market Position |
9 |
Eledon is uniquely positioned as the "operating system" for the xenotransplantation revolution and leads in the T1D islet cell niche.[3] |
| Growth Outlook |
9 |
If tegoprubart succeeds in kidney, the expansion into liver, T1D, and potentially ALS provides a multi-decade growth trajectory.[5, 20] |
| Financial Health |
5 |
The current \$133M cash is healthy for a small-cap biotech, but the long-term capital intensity of Phase 3 remains a structural concern.[1, 10] |
| Business Viability |
7 |
The CD40L target is well-validated, and the modified Fc region provides a structural defense against earlier class failures.[7, 19] |
| Capital Allocation |
6 |
Successful \$57.5M fundraising in 2025 shows market support, but the proposed increase in authorized shares to 450M indicates high future capital needs.[34, 38] |
| Analyst Sentiment |
9 |
Overwhelmingly positive; consensus "Strong Buy" with massive upside targets from most major healthcare boutiques.[31, 32, 39] |
| Profitability |
1 |
Operating losses are significant and expected to widen as Phase 3 begins.[1, 20] |
| Track Record |
6 |
Management has hit clinical milestones on time (BESTOW readout, UChicago enrollment) but has yet to manage a successful commercial launch.[1, 3, 8] |
| Blended Score |
6.1 |
Strong clinical-stage contender. |
SPECULATIVE CORE HOLDING.
7. Conclusion & Investment Thesis
Eledon Pharmaceuticals is at a pivotal inflection point. The traditional standard of care in transplantation is ripe for disruption, as patients and physicians increasingly demand therapies that do not sacrifice the organ's health to prevent its rejection. Tegoprubart has demonstrated the potential to solve this "toxic trade-off" by providing robust immunosuppression with a vastly superior safety profile.[3, 7, 8]
The investment thesis is anchored by three key pillars:
1. Clinical Validation: The Phase 2 BESTOW trial successfully de-risked the kidney program by proving non-inferiority to tacrolimus in survival and organ function, while showing significant reductions in tremors and diabetes.[3, 8]
2. Platform Expansion: The success in T1D islet cell transplantation (100% insulin independence in initial patients) and its role in xenotransplantation at MGH expand Eledon’s TAM far beyond the traditional transplant market.[3, 4]
3. Strategic Opportunity: As one of the few independent companies with a Phase 3-ready anti-CD40L asset, Eledon is a prime candidate for acquisition or a lucrative partnership with Big Pharma as the sector searches for the next generation of immunology blockbusters.[9, 22]
While investors must be wary of the inevitable dilution and the high-stakes binary nature of Phase 3 trials, the current valuation does not appear to fully account for the potential for tegoprubart to become a new standard of care.
HIGH-CONVICTION BIOTECH SPECULATION.
8. Technical Analysis, Price Action & Short-Term Outlook
Eledon's stock (ELDN) has exhibited strong technical momentum in early 2026, trading near \$3.34 - \$3.48, which is well above its 200-day simple moving average (SMA) of \$2.43 and its 50-day SMA of \$2.78.[40, 41] The Relative Strength Index (RSI) is neutral at 54.49, suggesting the stock is not overbought despite its year-to-date rally.[42] Short-term outlook remains positive as the company approaches its Q1 2026 earnings report in May, where further clarity on Phase 3 FDA guidance could serve as a catalyst for a breakout above recent 52-week highs of \$4.60.[29, 31, 40]
STRONG TRENDING MOMENTUM.
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - GlobeNewswire, https://www.globenewswire.com/news-release/2026/03/19/3259477/0/en/Eledon-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2025-Operating-and-Financial-Results.html
- Organ Transplant Immunosuppressant Drugs Market Size, Trends & Data Insight, https://www.towardshealthcare.com/insights/organ-transplant-immunosuppressant-drugs-market-sizing
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook, https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-highlights-recent-business-milestones-1
- Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine, https://ir.eledon.com/news-releases/news-release-details/eledon-announces-updated-data-investigator-initiated-islet
- Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation, https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-announces-orphan-drug-designation-0
- Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference, https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-participate-leerink-partners-2026-global
- Long-Term Outcomes of a Phase 1, Single-Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD4 - Eledon Pharmaceuticals, Inc., https://ir.eledon.com/static-files/061965c5-b641-4a71-8a40-2fa998b7ba14
- Eledon Pharmaceuticals at Leerink Conference: Strategic Insights on Transplantation, https://www.investing.com/news/transcripts/eledon-pharmaceuticals-at-leerink-conference-strategic-insights-on-transplantation-93CH-4555649
- Eledon's Transplant Drug Is Heading Toward A Phase 3 Moment - Finimize, https://finimize.com/content/eldn-asset-snapshot
- Eledon (NASDAQ: ELDN) 2025 results show higher R&D spend and cash - Stock Titan, https://www.stocktitan.net/sec-filings/ELDN/10-k-eledon-pharmaceuticals-inc-files-annual-report-6912321fc330.html
- Kidney Transplant Rejection Market Size is Expected to Reach USD 6,647 million in 2034., https://www.delveinsight.com/insights/kidney-transplant-rejection-market-size
- EDGAR Entity Landing Page - SEC.gov, https://sec.gov/edgar/browse/?CIK=1701541
- Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium, https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-presents-long-term-phase-1b-data
- CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight - PR Newswire, https://www.prnewswire.com/news-releases/cd40cd40l-inhibitors-market-on-growth-trajectory-driven-by-advancements-in-autoimmune-and-cancer-therapeutics--delveinsight-302512953.html
- How Much Is Tacrolimus Without Insurance? - GoodRx, https://www.goodrx.com/tacrolimus/how-much-is-tacrolimus-without-insurance
- Transplant Recipients Using Tacrolimus Had Higher Utilization of Healthcare Services Than Those Receiving Cyclosporine in Taiwan - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC6761300/
- Kidney Transplant Market Size & Share| Industry Report, 2030 - Grand View Research, https://www.grandviewresearch.com/industry-analysis/kidney-transplant-market-report
- Eledon gets FDA Orphan Drug designation for liver | ELDN Stock News, https://www.stocktitan.net/news/ELDN/eledon-pharmaceuticals-announces-orphan-drug-designation-granted-to-ljf6hd5tqjhn.html
- Organ transplant rejection drug pipeline review - PatSnap, https://www.patsnap.com/de/resources/blog/articles/organ-transplant-rejection-drug-pipeline-review/
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results, https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2025
- Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era - AAKP, https://aakp.org/wp-content/uploads/2019/11/JASN-Kadatz-Economics-Medicare-Immuno.pdf
- CD40/CD40L Inhibitors Market Size, Drugs, Companies, Insights - DelveInsight, https://www.delveinsight.com/report-store/cd40-cd40l-market
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation - Sanofi, https://www.sanofi.com/en/clinical-trials/nct07412470
- NCT07412470 | A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT07412470
- Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity, https://investors.biogen.com/news-releases/news-release-details/dapirolizumab-pegol-phase-3-data-sle-presented-annual-european
- The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC4520417/
- A population-based analysis of immunosuppression therapy after organ transplantation, https://pmc.ncbi.nlm.nih.gov/articles/PMC12082922/
- Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results, https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-first-quarter-2025-operating-and
- Eledon Pharmaceuticals (ELDN) Earnings: Latest Report, Earnings Call & Financials, https://public.com/stocks/eldn/earnings
- ELEDON PHARMACEUTICALS ($ELDN) Releases Q4 2025 Earnings, Stock Rises, https://www.quiverquant.com/news/ELEDON+PHARMACEUTICALS+%28%24ELDN%29+Releases+Q4+2025+Earnings%2C+Stock+Rises
- ELEDON PHARMACEUTICALS INC (ELDN) Forecast, Price Target & Analyst Ratings, https://www.chartmill.com/stock/quote/ELDN/analyst-ratings
- ELDN / Eledon Pharmaceuticals, Inc. (NasdaqCM) - Forecast, Price Target, Estimates, Predictions - Fintel, https://fintel.io/sfo/us/eldn
- What is the current Price Target and Forecast for Eledon Pharmaceuticals (ELDN) - Zacks, https://www.zacks.com/stock/research/ELDN/price-target-stock-forecast
- Eledon proxy seeks share increase and board votes | ELDN Proxy ..., https://www.stocktitan.net/sec-filings/ELDN/def-14a-eledon-pharmaceuticals-inc-definitive-proxy-statement-875dbb6ce668.html
- Eledon Pharmaceuticals Stock Price | ELDN Stock Quote, News, and History, https://markets.businessinsider.com/stocks/eldn-stock
- Eledon Pharmaceuticals Stock Forecast & Predictions: 1Y Price Target $8.00 | Buy or Sell NASDAQ: ELDN 2026 | WallStreetZen, https://www.wallstreetzen.com/stocks/us/nasdaq/eldn/stock-forecast
- Eledon Pharmaceuticals, Inc. Insider Trading & Ownership Structure - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eldn/eledon-pharmaceuticals/ownership
- Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results, https://ir.eledon.com/node/10926/pdf
- Eledon Pharmaceuticals (ELDN) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 - Public Investing, https://public.com/stocks/eldn/forecast-price-target
- Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat, https://www.marketbeat.com/instant-alerts/eledon-pharmaceuticals-inc-nasdaqeldn-receives-consensus-recommendation-of-hold-from-analysts-2026-04-21/
- Eledon Pharmaceuticals - 12 Year Stock Price History | ELDN - Macrotrends, https://www.macrotrends.net/stocks/charts/ELDN/eledon-pharmaceuticals/stock-price-history
- ELDN Technical Analysis | Trend, Signals & Chart Patterns | ELEDON PHARMACEUTICALS INC (NASDAQ:ELDN) | ChartMill.com, https://www.chartmill.com/stock/quote/ELDN/technical-analysis